Chronic Stable Angina - Pipeline Insight, 2019 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Jan 22, 2019--The “Chronic Stable Angina - Pipeline Insight, 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.
This report offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Chronic Stable Angina development.
The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.
Pipeline Products covered across the following Developmental Stages:Clinical Non-clinical Inactive: Discontinued and/or Dormant
Descriptive coverage of pipeline development activities for Chronic Stable Angina
Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.
Pipeline Therapeutics assessment of products for Chronic Stable Angina
The report assesses the active Chronic Stable Angina pipeline products by developmental stage, product type, molecule type, and administration route.
Companies FeaturedAstraZeneca Pfizer Sinphar Pharmaceutical Co. Ltd. Bayer AstraZeneca Amgen Chong Kun Dang Pharmaceutical Euro CTO Club
1. Report Introduction
2. Chronic Stable Angina Overview
3. Pipeline Therapeutics
4. Comparative Analysis
5. Products in Clinical Stage
6. Products in Pre-Clinical & Discovery Stage
7. Therapeutic Assessment
8. Inactive Products
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/cc769d/chronic_stable?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20190122005476/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Cardiovascular Drugs
INDUSTRY KEYWORD: HEALTH CARDIOLOGY PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2019.
PUB: 01/22/2019 06:54 AM/DISC: 01/22/2019 06:54 AM